Navigation Links
Cohera Medical Named Winner of 2013 Carnegie Science Award
Date:1/31/2013

to reduce the fluid that can accumulate in the space during healing and ultimately reducing the need for postoperative drains to remove the fluid. The ability to perform the procedure without drains would lead to a more comfortable recovery and a quicker return to normal activity for patients.

Winners for the Carnegie Science Awards will be honored during a formal celebration at Carnegie Music Hall on May 3, 2013.

About Cohera Medical

Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains.  TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU).  Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.  For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materi
'/>"/>

SOURCE Cohera Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
2. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
3. TI introduces lowest-power octal, 100-MSPS ADC for medical, industrial imaging applications
4. NICB Report On Durable Medical Equipment Fraud
5. Solta Medical to Acquire Sound Surgical Technologies
6. NSF International Acquires the INASSA Group LLC, a Peruvian Leader in Analytical Testing, Certification, Inspection and Training for the Seafood/Fishing, Food and Pharmaceutical/Medical Industries
7. New Pre-Clinical and Clinical Data on GeNO LLCs Nitric Oxide Delivery Systems to Be Presented at 2013 American College of Cardiology and American Thoracic Society Medical Meetings
8. Aethlon Medical Discloses CEO Interview
9. Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
10. The International EECP Therapists Association and Vasomedical Announce Second Annual EECP Therapy Week
11. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... -- Whole-cell pertussis vaccines were more effective at protecting against ... outbreak, according to a new Kaiser Permanente study published ... DTwP, were available from the 1940s to 1990s, but ... the development of acellular pertussis vaccines, which are also ... United States had switched from whole-cell to ...
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
... adding Diovan to conventional therapy , , , Study ... , , BASEL,Switzerland, April 27, 2007 ... published today in The Lancet[1], show that,adding the blood ... 39% reduction in,cardiovascular events and a 40% reduction in ...
Cached Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:5/20/2013)... Adeptia Inc., a leading ... process integration solutions, today announced the availability ... solution. Version 6.0 is the only ... business processes involving data access, validation, transformation, ... interaction for real-time decision-making and exception-handling. The ...
(Date:5/20/2013)... Although many hospital intensive care units have a ... outcomes, new research suggests this may have no ... teaching hospitals in the United States and three-quarters ... in the ICU, the practice may unnecessarily increase ... with fewer resources, the study authors said. ...
(Date:5/20/2013)... NY (PRWEB) May 20, 2013 In ... of the numerous scientific accomplishments achieved at The ... group of female scientists, Advancing Women in Science ... breakfast on May 17. Scientists, educators, business and ... celebrate excellence and achievements of women in science. ...
(Date:5/20/2013)... toothpaste that transforms the sweet flavor of orange juice ... mysterious sensory phenomenon in colorful, animated detail ... award-winning Bytesize Science video series at ... scientific society, explains that the mainstay ingredients in toothpaste ... for short. When you brush your teeth, SLS produces ...
(Date:5/20/2013)... 2013) Wolters Kluwer Health is ... Wilkins (LWW) published journals won 13 ASHPE awards ... member articles and publications for editorial, design, print ... honor to be recognized year after year for ... the industry with quality, depth, and impact," said ...
Breaking Medicine News(10 mins):Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2
... of Charity Health System Bargaining in Bad Faith, ... operated throughout California by the Daughters of,Charity Health System ... Caregivers represented by SEIU United Healthcare Workers-West have been,bargaining ... But,management has refused to make any economic proposals, and ...
... WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals, a ... and inflammation, today announced that on August 14, ... stating that, for the last,30 consecutive trading days, ... market value of publicly held shares ("MVPHS") of ...
... YORK, Aug. 15 The Hereditary Disease Foundation,(HDF) ... Administration has,approved Xenazine, or tetrabenazine, for the treatment ... a major cause of disability and death in ... mere inconvenience; it can,prevent Huntington,s disease patients from ...
... Food and Drug Administration today approved tetrabenazine, the first ... treat Huntington,s disease, a fatal, inherited neurodegenerative disorder for ... eight months after an advisory panel unanimously voted to ... the disease. , The drug is already widely used ...
... in a dangerously abnormal way, a series of death signals ... research to appear in the August 15 issue of ... a way in mice to amplify the signals that tell ... that normally helps cells to avoid self-destruction. , The work, ...
... , ... London, UK (PRWEB) August 15, 2008 -- X Factor star and mother of ... [MYA Cosmetic Surgery]. The 36 year old, who is well known ... MYA and in total has lost 6 inches from her waist, 4 inches ...
Cached Medicine News:Health News:NUCRYST Receives Deficiency Notice from NASDAQ 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 3Health News:FDA approves first drug for Huntington's disease 2Health News:FDA approves first drug for Huntington's disease 3Health News:FDA approves first drug for Huntington's disease 4Health News:By amplifying cell death signals, scientists make precancerous cells self-destruct 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: